Literature DB >> 2269277

Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro.

N Imai1, M Higuchi, A Kawamura, K Tomonoh, M Oh-Eda, M Fujiwara, Y Shimonaka, N Ochi.   

Abstract

Various partially or fully desialylated human erythropoietins were obtained by neuraminidase digestion of the hormone, without non-specific proteolysis and degradation of carbohydrates. Asialoerythropoietin showed a specific activity of 220-IU/mg protein in vivo, although that of the intact erythropoietin was 2.2 x 10(5) IU/mg. A linear relationship was found between the logarithm of the specific activity in vivo and the number of sialic acids. The asialoerythropoietin showed a four-times-higher specific activity in vitro compared with intact erythropoietin using mouse bone marrow cells. It also showed an approximately six-times-higher specific activity in a colony-forming assay for the erythroid colony-forming unit and the erythroid burst-forming unit. Partially or fully de-N-glycosylated erythropoietin derivatives also showed lower in vivo activity but higher in vitro activity than the intact erythropoietin, dependent on the number of sialic acids. To clarify the reason for the enhanced biological activity of asialoerythropoietin in vitro, the binding of intact 125I-erythropoietin or 125I-asialoerythropoietin to cells containing specific receptors for the hormone was analyzed. 125I-asialoerythropoietin bound to spleen cells from anemic mice approximately five times faster than did intact 125I-erythropoietin. The amount of 125I-asialoerythropoietin internalized by target cells, measured in the absence of NaN3, was four times higher than that of intact erythropoietin. These results demonstrate that asialoerythropoietin binds to its receptor faster than the intact form. This may be the main reason for the increased activity of asialoerythropoietin in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2269277     DOI: 10.1111/j.1432-1033.1990.tb15639.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells.

Authors:  François Lefloch; Bertrand Tessier; Sébastien Chenuet; Jean-Marc Guillaume; Pierre Cans; Jean-Louis Goergen; Annie Marc
Journal:  Cytotechnology       Date:  2006-12-29       Impact factor: 2.058

2.  Biological and physicochemical characterization of recombinant human erythropoietins fractionated by Mono Q column chromatography and their modification with sialyltransferase.

Authors:  K Morimoto; E Tsuda; A A Said; E Uchida; S Hatakeyama; M Ueda; T Hayakawa
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

3.  Effects of erythropoietin on angiogenesis after myocardial infarction in porcine.

Authors:  Keisuke Kawachi; Yoshitaka Iso; Takatoshi Sato; Kohei Wakabayashi; Youichi Kobayashi; Youichi Takeyama; Hiroshi Suzuki
Journal:  Heart Vessels       Date:  2011-10-29       Impact factor: 2.037

4.  Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury.

Authors:  Bo Wang; Mitchell Kang; Michelle Marchese; Esther Rodriguez; Wei Lu; Xintong Li; Yasuhiro Maeda; Peter Dowling
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

5.  Glycosylation-modified erythropoietin with improved half-life and biological activity.

Authors:  Dongmei Su; Huilin Zhao; Huanzhang Xia
Journal:  Int J Hematol       Date:  2010-02-05       Impact factor: 2.490

Review 6.  Role of erythropoietin in the brain.

Authors:  Constance Tom Noguchi; Pundit Asavaritikrai; Ruifeng Teng; Yi Jia
Journal:  Crit Rev Oncol Hematol       Date:  2007-05-04       Impact factor: 6.312

7.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

Authors:  Serhat Erbayraktar; Giovanni Grasso; Alessandra Sfacteria; Qiao-wen Xie; Thomas Coleman; Mads Kreilgaard; Lars Torup; Thomas Sager; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Pietro Ghezzi; Pia Villa; Maddalena Fratelli; Simona Casagrande; Marcel Leist; Lone Helboe; Jens Gerwein; Søren Christensen; Marie Aavang Geist; Lars Østergaard Pedersen; Carla Cerami-Hand; Jean-Paul Wuerth; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

8.  Beneficial effect of desialylated erythropoietin administration on the frozen-thawed canine ovarian xenotransplantation.

Authors:  Hiroshi Suzuki; Takako Ishijima; Saori Maruyama; Yoshiko Yanagimoto Ueta; Yasuyuki Abe; Hideki Saitoh
Journal:  J Assist Reprod Genet       Date:  2008-10-30       Impact factor: 3.412

9.  Asialoerythropoietin prevents contrast-induced nephropathy.

Authors:  Yukiyo Yokomaku; Toshiro Sugimoto; Shinji Kume; Shin-ichi Araki; Keiji Isshiki; Masami Chin-Kanasaki; Masayoshi Sakaguchi; Norihisa Nitta; Masakazu Haneda; Daisuke Koya; Takashi Uzu; Atsunori Kashiwagi
Journal:  J Am Soc Nephrol       Date:  2008-01-09       Impact factor: 10.121

10.  Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plants.

Authors:  Farooqahmed S Kittur; Mamudou Bah; Stephanie Archer-Hartmann; Chiu-Yueh Hung; Parastoo Azadi; Mayumi Ishihara; David C Sane; Jiahua Xie
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.